Kipspharma Files PCT International Patent for Oral Platform 'Oraloid', Ramping Up Global Rights Acquisition

Kipsbiopharma (Kipspharma) has embarked on securing global intellectual property rights for 'Oraloid™,' the oral drug delivery platform developed by its subsidiary, Kipsbiomed.

On August 10, Kipspharma announced that it has completed an international patent application under the Patent Cooperation Treaty (PCT) for the primary composition of Oraloid.

Previously, Kipsbiomed filed a domestic patent application for Oraloid last year. With this PCT application, the company has established a foundation to pursue subsequent procedures for obtaining patent rights in key markets such as the United States, Europe, Japan, and China.

The PCT is an international patent system that allows applicants to initiate patent acquisition procedures in multiple countries with a single international application. While an international application itself does not guarantee patents in individual countries, it provides a basis for developing entry and protection strategies for each nation in the future.

The core of this newly filed patent is to protect the key composition of Oraloid itself. According to the company, since the right is secured over a substance formed by combining specific ingredients and structures, it is significantly more difficult for competitors to circumvent the patent simply by making structural changes. This strengthens the platform technology's intellectual property defensibility.

Oraloid is a drug delivery platform that enhances the absorption rate of peptide pharmaceuticals, which are typically difficult to administer orally.

Peptide drugs have traditionally been developed in injectable forms due to their large molecular size and the fact that they are easily broken down by stomach acid and digestive enzymes. Oraloid surrounds the peptide with a calcium-based mineral component, which inhibits degradation by stomach acid and digestive enzymes and increases absorption in the small intestine.

The company particularly emphasizes Oraloid's potential as a universal platform that aims to improve oral absorption without altering the peptide drug's structure, thereby allowing application to various pharmaceuticals rather than being limited to a single product.

In practice, development is currently focused on oral insulin. Kipsbiomed plans to present research results on oral insulin utilizing the Oraloid platform in an oral presentation at the European Association for the Study of Diabetes (EASD) conference this September.

Oral insulin is an area of high market interest because it could improve the convenience of drug administration compared to the traditional injection method. If Oraloid proves efficacy and safety in the clinical and subsequent development stages, there is potential to expand its application to a wide range of peptide pharmaceuticals, including insulin.

Kipspharma intends to use this PCT application as a springboard to accelerate securing intellectual property rights for Oraloid in major global markets beyond Korea. At the same time, the company plans to enhance the commercialization potential of the platform by concurrently advancing conference presentations, pipeline development, and global partnering efforts.

A Kipspharma representative stated, "The development of our pipeline is progressing smoothly in line with our schedule, including patent application and conference presentations for Oraloid," adding, "We will accelerate our development efforts to enter clinical stages while steadily pursuing ongoing global partnering discussions."

This content was produced with the assistance of AI translation services.